1. Myeloid Updates From the Summer Congresses

2. Program Overview

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Newly Diagnosed Acute Myeloid Leukemia

5. Untreated AML The Current Landscape

6. CPX-351 Phase 3 Trial Design

7. CPX-351 vs 7 + 3 Older ND High-Risk AML

8. CPX-351 Subset Analysis

9. CPX-351 AEs

10. CPX-351 Consolidation as Outpatient Therapy

11. CPX-351 Subset Analysis

12. FLT3-Mutated AML

13. FLT3 Mutated AML CALGB 10603 Results

14. Other FLT3 Inhibitors Crenolanib

15. Crenolanib MRD Assessment

16. Updates on Other Novel Agents Sorafenib

17. New Approaches in TP53-Associated AML

18. New Approaches in TP53-Associated AML HMAs

19. Updates on Other Novel Agents Venetoclax Plus Low-Dose Cytarabine

20. Updates on Other Novel Agents Venetoclax Plus HMAs

21. Risk-Adapted Approach in AML GIMEMA, AML1310

22. Risk-Adapted Approach in AML Results

23. Key Takeaways

24. Relapsed and Refractory Acute Myeloid Leukemia

25. Overview

26. IDH Mutations

27. Novel Therapies in R/R AML Enasidenib

28. Enasidenib Overall Efficacy

29. Enasidenib Key Toxicities

30. Novel Therapies in R/R AML Gilteritinib

31. Gilteritinib Subset Analysis

32. Novel Therapies in R/R AML Quizartinib

33. Gene Testing in AML

34. Myelodysplastic Syndromes

35. MDS Treatment Higher-Risk Patients

36. MDS Treatment Lower-Risk Patients

37. Updates on Checkpoint Inhibitors Ipilimumab

38. Updates on Checkpoint Inhibitors Ipilimumab Posttransplantation

39. Updates on Checkpoint Inhibitors Nivolumab/Ipilimumab

40. Updates on Other New Agents Rigosertib

41. Updates on Other New Agents Vosaroxin

42. Updates on Other New Agents Guadecitabine

43. Key Takeaways

44. Myeloproliferative Neoplasms

45. Ruxolitinib vs BAT in Polycythemia Vera RESPONSE-2 Trial

46. Long-Acting Interferon in PV PILOT-PV Trial

47. PILOT-PV Trial Subset Analysis

48. Novel JAK Inhibitors in MF: Momelotinib SIMPLIFY-1 Trial

49. Novel JAK Inhibitors in MF: Momelotinib SIMPLIFY-2 Trial

50. Novel JAK Inhibitors in MF: Pacritinib PERSIST-2 Trial

51. PERSIST-2 Trial Subset Analysis

52. Combination Therapy in MF AZA Plus RUX

53. Abbreviations

54. Abbreviations (cont)

55. Abbreviations (cont)

56. Abbreviations (cont)

57. Abbreviations (cont)

58. Abbreviations (cont)

59. Abbreviations (cont)